Assessing and Modulating Immune Recovery After Transplant
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.
This study is testing whether a new way to track and support patients after a specific type of stem cell transplant can help them recover their immune system better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 456 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06208137 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of the Composite Immune Risk Score in managing patients who have undergone haploidentical allo-HSCT. It focuses on health monitoring and providing regular follow-up reminders to improve patient outcomes. The goal is to assess how these interventions can enhance immune reconstitution in a real-world clinical setting. By tracking patients' immune responses, the study aims to identify effective strategies for post-transplant care.
Who should consider this trial
Good fit: Ideal candidates are patients aged 16 and older who are receiving haploidentical allo-HSCT.
Not a fit: Patients undergoing tandem or multiple transplantations or those with conditions that prevent compliance may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved immune recovery and overall health outcomes for transplant patients.
How similar studies have performed: While the specific approach may be novel, similar studies focusing on immune monitoring post-transplant have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Patients must be ≥ 16 years of age; * 2\) Patients receiving haploidentical allo-HSCT; * 3\) Patients have to sign an informed consent form before the start of the research procedure. Exclusion Criteria: * 1\) Tandem transplantation or multiple transplantations; * 2\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements; * 3\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Where this trial is running
Tianjin, Tianjin Municipality
- Institute of Hematology & Blood Diseases Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yahui Feng, MS
- Email: fengyahui@ihcams.ac.cn
- Phone: 022-23909051
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.